Insomnia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Insomnia is the most common clinical condition in which the person experiences difficulty sleeping and is subclassified as short-term, chronic, and other. Sometimes it is described as the presence of polysomnographic evidence of disturbed sleep. Therefore, insomnia is considered to exist when there is long sleep latency, frequent nocturnal awakening, prolonged wakefulness throughout the sleep phase, or transient arousals. Insomnia can be a primary sleep disorder, comorbid sleep condition, and other mental or medical disorders. The etiology includes environmental, genetic, behavioral, and physiological factors culminating in hyperarousal. Insomnia is the complex interaction between cognitive arousal, altered circulation, and the homeostatic system. Decreased function of the sleep-walk switch may also contribute to insomnia. During sleep, there is a gradual shift from non-rapid-eye movement (non-REM) sleep to rapid-eye-movement (REM) sleep. The most common symptom was trouble sustaining sleep (61%), followed by early morning awakening (2.2%), difficulties beginning sleep (7.7%), and nonrestorative sleep (7.7%). The American Academy of Sleep Medicine divides rest into five stages: Stage W (wakefulness), Stage N1 (relaxed wakefulness), Stage N2 (light sleep), Stage N3 (deep or slow-wave sleep), and Stage R (REM sleep or dreaming). N1-N3 are non-REM sleep stages with minimal cortical activity, whereas REM sleep has significant cortical activity.

  • In the U.S., approximately 30% to 40% of adults have insomnia. Short-term insomnia has an estimated prevalence of 9.5%, and 1 in 5 cases of short-term insomnia progresses to chronic insomnia. People with poor health or impaired quality of life are more likely to suffer from insomnia (QOL).

Thelansis’s “Insomnia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Insomnia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Insomnia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Insomnia  Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

 

Read more: Insomnia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more